nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—PPARG—urinary bladder cancer	0.5	1	CbGaD
Rosiglitazone—CYP2A6—Fluorouracil—urinary bladder cancer	0.0452	0.173	CbGbCtD
Rosiglitazone—PTGS1—Etoposide—urinary bladder cancer	0.0323	0.124	CbGbCtD
Rosiglitazone—SLCO1B1—Methotrexate—urinary bladder cancer	0.0291	0.111	CbGbCtD
Rosiglitazone—ALB—Fluorouracil—urinary bladder cancer	0.0289	0.111	CbGbCtD
Rosiglitazone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0223	0.0855	CbGbCtD
Rosiglitazone—CYP2C8—Etoposide—urinary bladder cancer	0.0186	0.0714	CbGbCtD
Rosiglitazone—CYP1A2—Fluorouracil—urinary bladder cancer	0.0173	0.0662	CbGbCtD
Rosiglitazone—ALB—Methotrexate—urinary bladder cancer	0.0159	0.061	CbGbCtD
Rosiglitazone—CYP2C9—Fluorouracil—urinary bladder cancer	0.0156	0.0596	CbGbCtD
Rosiglitazone—CYP1A2—Etoposide—urinary bladder cancer	0.0144	0.0552	CbGbCtD
Rosiglitazone—CYP2C9—Cisplatin—urinary bladder cancer	0.0132	0.0507	CbGbCtD
Rosiglitazone—CYP2D6—Doxorubicin—urinary bladder cancer	0.0081	0.031	CbGbCtD
Rosiglitazone—ACSL4—prostate gland—urinary bladder cancer	0.00371	0.0693	CbGeAlD
Rosiglitazone—CYP2C19—urine—urinary bladder cancer	0.00351	0.0656	CbGeAlD
Rosiglitazone—ACSL4—seminal vesicle—urinary bladder cancer	0.00314	0.0586	CbGeAlD
Rosiglitazone—CYP1A2—urine—urinary bladder cancer	0.00287	0.0536	CbGeAlD
Rosiglitazone—Pioglitazone—PPARG—urinary bladder cancer	0.00273	1	CrCbGaD
Rosiglitazone—CYP2C9—urine—urinary bladder cancer	0.00272	0.0509	CbGeAlD
Rosiglitazone—ACSL4—renal system—urinary bladder cancer	0.00253	0.0473	CbGeAlD
Rosiglitazone—ACSL4—urethra—urinary bladder cancer	0.00249	0.0464	CbGeAlD
Rosiglitazone—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.00229	1	CbGdCrCtD
Rosiglitazone—CYP2D6—urine—urinary bladder cancer	0.00204	0.0382	CbGeAlD
Rosiglitazone—ACSL4—female reproductive system—urinary bladder cancer	0.00203	0.0378	CbGeAlD
Rosiglitazone—CYP2A6—prostate gland—urinary bladder cancer	0.00196	0.0366	CbGeAlD
Rosiglitazone—ACSL4—vagina—urinary bladder cancer	0.00183	0.0342	CbGeAlD
Rosiglitazone—PPARG—prostate gland—urinary bladder cancer	0.00167	0.0312	CbGeAlD
Rosiglitazone—CYP2A6—seminal vesicle—urinary bladder cancer	0.00166	0.031	CbGeAlD
Rosiglitazone—SLCO1B1—renal system—urinary bladder cancer	0.00132	0.0246	CbGeAlD
Rosiglitazone—PPARG—epithelium—urinary bladder cancer	0.00123	0.0229	CbGeAlD
Rosiglitazone—ACSL4—lymph node—urinary bladder cancer	0.00119	0.0221	CbGeAlD
Rosiglitazone—PPARG—smooth muscle tissue—urinary bladder cancer	0.00118	0.0221	CbGeAlD
Rosiglitazone—PPARG—renal system—urinary bladder cancer	0.00114	0.0213	CbGeAlD
Rosiglitazone—PPARG—urethra—urinary bladder cancer	0.00112	0.0209	CbGeAlD
Rosiglitazone—SLCO1B1—female reproductive system—urinary bladder cancer	0.00106	0.0197	CbGeAlD
Rosiglitazone—CYP2A6—vagina—urinary bladder cancer	0.000968	0.0181	CbGeAlD
Rosiglitazone—PPARG—female reproductive system—urinary bladder cancer	0.000912	0.017	CbGeAlD
Rosiglitazone—PTGS1—prostate gland—urinary bladder cancer	0.000893	0.0167	CbGeAlD
Rosiglitazone—PPARG—vagina—urinary bladder cancer	0.000824	0.0154	CbGeAlD
Rosiglitazone—PTGS1—seminal vesicle—urinary bladder cancer	0.000755	0.0141	CbGeAlD
Rosiglitazone—CYP2C8—renal system—urinary bladder cancer	0.00075	0.014	CbGeAlD
Rosiglitazone—CYP1A2—renal system—urinary bladder cancer	0.000702	0.0131	CbGeAlD
Rosiglitazone—PTGS1—epithelium—urinary bladder cancer	0.000656	0.0123	CbGeAlD
Rosiglitazone—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000632	0.0118	CbGeAlD
Rosiglitazone—CYP2C19—vagina—urinary bladder cancer	0.000623	0.0116	CbGeAlD
Rosiglitazone—PTGS1—renal system—urinary bladder cancer	0.000608	0.0114	CbGeAlD
Rosiglitazone—CYP2C8—female reproductive system—urinary bladder cancer	0.000601	0.0112	CbGeAlD
Rosiglitazone—CYP2C8—vagina—urinary bladder cancer	0.000543	0.0102	CbGeAlD
Rosiglitazone—CYP2C9—female reproductive system—urinary bladder cancer	0.000534	0.00997	CbGeAlD
Rosiglitazone—PPARG—lymph node—urinary bladder cancer	0.000533	0.00996	CbGeAlD
Rosiglitazone—ALB—lymph node—urinary bladder cancer	0.0005	0.00934	CbGeAlD
Rosiglitazone—CYP2D6—renal system—urinary bladder cancer	0.0005	0.00934	CbGeAlD
Rosiglitazone—PTGS1—female reproductive system—urinary bladder cancer	0.000487	0.0091	CbGeAlD
Rosiglitazone—PTGS1—vagina—urinary bladder cancer	0.000441	0.00823	CbGeAlD
Rosiglitazone—CYP2D6—female reproductive system—urinary bladder cancer	0.000401	0.00748	CbGeAlD
Rosiglitazone—Myocardial infarction—Cisplatin—urinary bladder cancer	0.00036	0.00373	CcSEcCtD
Rosiglitazone—Back pain—Thiotepa—urinary bladder cancer	0.000354	0.00367	CcSEcCtD
Rosiglitazone—Nausea—Mitomycin—urinary bladder cancer	0.000353	0.00366	CcSEcCtD
Rosiglitazone—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000349	0.00361	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000348	0.0036	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000348	0.0036	CcSEcCtD
Rosiglitazone—Hyperbilirubinaemia—Doxorubicin—urinary bladder cancer	0.000343	0.00356	CcSEcCtD
Rosiglitazone—Anaemia—Thiotepa—urinary bladder cancer	0.000339	0.00351	CcSEcCtD
Rosiglitazone—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000335	0.00347	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000334	0.00346	CcSEcCtD
Rosiglitazone—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000332	0.00344	CcSEcCtD
Rosiglitazone—Myocardial infarction—Etoposide—urinary bladder cancer	0.00033	0.00342	CcSEcCtD
Rosiglitazone—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000329	0.0034	CcSEcCtD
Rosiglitazone—Leukopenia—Thiotepa—urinary bladder cancer	0.000328	0.0034	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000324	0.00336	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.000321	0.00332	CcSEcCtD
Rosiglitazone—Fluid retention—Epirubicin—urinary bladder cancer	0.00032	0.00332	CcSEcCtD
Rosiglitazone—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00032	0.00331	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000319	0.0033	CcSEcCtD
Rosiglitazone—Hypertension—Thiotepa—urinary bladder cancer	0.000316	0.00328	CcSEcCtD
Rosiglitazone—Myalgia—Thiotepa—urinary bladder cancer	0.000312	0.00323	CcSEcCtD
Rosiglitazone—Arthralgia—Thiotepa—urinary bladder cancer	0.000312	0.00323	CcSEcCtD
Rosiglitazone—Eye disorder—Cisplatin—urinary bladder cancer	0.000308	0.00319	CcSEcCtD
Rosiglitazone—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000306	0.00317	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000301	0.00312	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.0003	0.00311	CcSEcCtD
Rosiglitazone—Back pain—Gemcitabine—urinary bladder cancer	0.000298	0.00309	CcSEcCtD
Rosiglitazone—Immune system disorder—Cisplatin—urinary bladder cancer	0.000298	0.00309	CcSEcCtD
Rosiglitazone—Infection—Thiotepa—urinary bladder cancer	0.000297	0.00308	CcSEcCtD
Rosiglitazone—Fluid retention—Doxorubicin—urinary bladder cancer	0.000296	0.00307	CcSEcCtD
Rosiglitazone—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000293	0.00304	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000293	0.00303	CcSEcCtD
Rosiglitazone—Hepatic failure—Methotrexate—urinary bladder cancer	0.000291	0.00302	CcSEcCtD
Rosiglitazone—Malnutrition—Cisplatin—urinary bladder cancer	0.000287	0.00298	CcSEcCtD
Rosiglitazone—Erythema multiforme—Etoposide—urinary bladder cancer	0.000286	0.00296	CcSEcCtD
Rosiglitazone—PTGS1—lymph node—urinary bladder cancer	0.000285	0.00532	CbGeAlD
Rosiglitazone—Anaemia—Gemcitabine—urinary bladder cancer	0.000285	0.00295	CcSEcCtD
Rosiglitazone—Eye disorder—Etoposide—urinary bladder cancer	0.000283	0.00293	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000282	0.00292	CcSEcCtD
Rosiglitazone—Cardiac disorder—Etoposide—urinary bladder cancer	0.000281	0.00291	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00028	0.0029	CcSEcCtD
Rosiglitazone—Anaemia—Fluorouracil—urinary bladder cancer	0.00028	0.0029	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.000278	0.00288	CcSEcCtD
Rosiglitazone—Leukopenia—Gemcitabine—urinary bladder cancer	0.000276	0.00286	CcSEcCtD
Rosiglitazone—Immune system disorder—Etoposide—urinary bladder cancer	0.000273	0.00283	CcSEcCtD
Rosiglitazone—Hepatic failure—Epirubicin—urinary bladder cancer	0.000273	0.00282	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000272	0.00282	CcSEcCtD
Rosiglitazone—Leukopenia—Fluorouracil—urinary bladder cancer	0.000271	0.00281	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.00027	0.0028	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000267	0.00277	CcSEcCtD
Rosiglitazone—Hypertension—Gemcitabine—urinary bladder cancer	0.000266	0.00276	CcSEcCtD
Rosiglitazone—Anaemia—Cisplatin—urinary bladder cancer	0.000266	0.00275	CcSEcCtD
Rosiglitazone—Arthralgia—Gemcitabine—urinary bladder cancer	0.000262	0.00272	CcSEcCtD
Rosiglitazone—Myalgia—Gemcitabine—urinary bladder cancer	0.000262	0.00272	CcSEcCtD
Rosiglitazone—Increased appetite—Epirubicin—urinary bladder cancer	0.000261	0.0027	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000261	0.0027	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000259	0.00269	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000258	0.00267	CcSEcCtD
Rosiglitazone—Myalgia—Fluorouracil—urinary bladder cancer	0.000258	0.00267	CcSEcCtD
Rosiglitazone—Fatigue—Thiotepa—urinary bladder cancer	0.000258	0.00267	CcSEcCtD
Rosiglitazone—Leukopenia—Cisplatin—urinary bladder cancer	0.000257	0.00266	CcSEcCtD
Rosiglitazone—Constipation—Thiotepa—urinary bladder cancer	0.000256	0.00265	CcSEcCtD
Rosiglitazone—Back pain—Etoposide—urinary bladder cancer	0.000255	0.00264	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000252	0.00261	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000252	0.00261	CcSEcCtD
Rosiglitazone—Oedema—Gemcitabine—urinary bladder cancer	0.000252	0.00261	CcSEcCtD
Rosiglitazone—Cardiac failure—Epirubicin—urinary bladder cancer	0.000251	0.0026	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000251	0.0026	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.00025	0.00259	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.00025	0.00259	CcSEcCtD
Rosiglitazone—Infection—Gemcitabine—urinary bladder cancer	0.00025	0.00259	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000247	0.00256	CcSEcCtD
Rosiglitazone—Oedema—Fluorouracil—urinary bladder cancer	0.000247	0.00256	CcSEcCtD
Rosiglitazone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000247	0.00255	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000246	0.00255	CcSEcCtD
Rosiglitazone—Infection—Fluorouracil—urinary bladder cancer	0.000246	0.00254	CcSEcCtD
Rosiglitazone—Myalgia—Cisplatin—urinary bladder cancer	0.000245	0.00253	CcSEcCtD
Rosiglitazone—Anaemia—Etoposide—urinary bladder cancer	0.000243	0.00252	CcSEcCtD
Rosiglitazone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000243	0.00251	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000242	0.00251	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—urinary bladder cancer	0.000241	0.0025	CcSEcCtD
Rosiglitazone—Urticaria—Thiotepa—urinary bladder cancer	0.000238	0.00246	CcSEcCtD
Rosiglitazone—Leukopenia—Etoposide—urinary bladder cancer	0.000236	0.00244	CcSEcCtD
Rosiglitazone—Oedema—Cisplatin—urinary bladder cancer	0.000234	0.00243	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000234	0.00243	CcSEcCtD
Rosiglitazone—Infection—Cisplatin—urinary bladder cancer	0.000233	0.00241	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000232	0.00241	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000232	0.00241	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000231	0.0024	CcSEcCtD
Rosiglitazone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00023	0.00238	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00023	0.00238	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000229	0.00237	CcSEcCtD
Rosiglitazone—Hypertension—Etoposide—urinary bladder cancer	0.000227	0.00235	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000225	0.00233	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000219	0.00227	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000217	0.00225	CcSEcCtD
Rosiglitazone—Fatigue—Gemcitabine—urinary bladder cancer	0.000217	0.00225	CcSEcCtD
Rosiglitazone—Constipation—Gemcitabine—urinary bladder cancer	0.000215	0.00223	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000215	0.00222	CcSEcCtD
Rosiglitazone—Asthenia—Thiotepa—urinary bladder cancer	0.000215	0.00222	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000214	0.00221	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000214	0.00221	CcSEcCtD
Rosiglitazone—Infection—Etoposide—urinary bladder cancer	0.000213	0.00221	CcSEcCtD
Rosiglitazone—Pruritus—Thiotepa—urinary bladder cancer	0.000212	0.00219	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00021	0.00218	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00021	0.00218	CcSEcCtD
Rosiglitazone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000205	0.00212	CcSEcCtD
Rosiglitazone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000203	0.0021	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000202	0.0021	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.0002	0.00207	CcSEcCtD
Rosiglitazone—Dizziness—Thiotepa—urinary bladder cancer	0.000198	0.00205	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000197	0.00204	CcSEcCtD
Rosiglitazone—Urticaria—Fluorouracil—urinary bladder cancer	0.000196	0.00203	CcSEcCtD
Rosiglitazone—Weight increased—Epirubicin—urinary bladder cancer	0.000193	0.002	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000191	0.00198	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000191	0.00198	CcSEcCtD
Rosiglitazone—Rash—Thiotepa—urinary bladder cancer	0.000189	0.00195	CcSEcCtD
Rosiglitazone—Dermatitis—Thiotepa—urinary bladder cancer	0.000188	0.00195	CcSEcCtD
Rosiglitazone—Headache—Thiotepa—urinary bladder cancer	0.000187	0.00194	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000187	0.00194	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000185	0.00192	CcSEcCtD
Rosiglitazone—Fatigue—Etoposide—urinary bladder cancer	0.000185	0.00192	CcSEcCtD
Rosiglitazone—Constipation—Etoposide—urinary bladder cancer	0.000184	0.0019	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000182	0.00189	CcSEcCtD
Rosiglitazone—Hepatitis—Methotrexate—urinary bladder cancer	0.000181	0.00188	CcSEcCtD
Rosiglitazone—Asthenia—Gemcitabine—urinary bladder cancer	0.00018	0.00187	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000179	0.00185	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—urinary bladder cancer	0.000178	0.00185	CcSEcCtD
Rosiglitazone—Pruritus—Gemcitabine—urinary bladder cancer	0.000178	0.00184	CcSEcCtD
Rosiglitazone—Nausea—Thiotepa—urinary bladder cancer	0.000178	0.00184	CcSEcCtD
Rosiglitazone—Sinusitis—Epirubicin—urinary bladder cancer	0.000177	0.00183	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000177	0.00183	CcSEcCtD
Rosiglitazone—Pruritus—Fluorouracil—urinary bladder cancer	0.000175	0.00181	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000173	0.00179	CcSEcCtD
Rosiglitazone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000172	0.00178	CcSEcCtD
Rosiglitazone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000171	0.00177	CcSEcCtD
Rosiglitazone—Urticaria—Etoposide—urinary bladder cancer	0.000171	0.00177	CcSEcCtD
Rosiglitazone—Hepatitis—Epirubicin—urinary bladder cancer	0.000169	0.00176	CcSEcCtD
Rosiglitazone—Eye disorder—Methotrexate—urinary bladder cancer	0.000169	0.00175	CcSEcCtD
Rosiglitazone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000169	0.00175	CcSEcCtD
Rosiglitazone—Asthenia—Cisplatin—urinary bladder cancer	0.000168	0.00174	CcSEcCtD
Rosiglitazone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000168	0.00174	CcSEcCtD
Rosiglitazone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000167	0.00173	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000167	0.00172	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000165	0.00171	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000164	0.0017	CcSEcCtD
Rosiglitazone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000164	0.00169	CcSEcCtD
Rosiglitazone—Dizziness—Fluorouracil—urinary bladder cancer	0.000164	0.00169	CcSEcCtD
Rosiglitazone—Diarrhoea—Cisplatin—urinary bladder cancer	0.00016	0.00166	CcSEcCtD
Rosiglitazone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00016	0.00166	CcSEcCtD
Rosiglitazone—Rash—Gemcitabine—urinary bladder cancer	0.000159	0.00164	CcSEcCtD
Rosiglitazone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000158	0.00164	CcSEcCtD
Rosiglitazone—Eye disorder—Epirubicin—urinary bladder cancer	0.000158	0.00164	CcSEcCtD
Rosiglitazone—Malnutrition—Methotrexate—urinary bladder cancer	0.000158	0.00163	CcSEcCtD
Rosiglitazone—Headache—Gemcitabine—urinary bladder cancer	0.000158	0.00163	CcSEcCtD
Rosiglitazone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000157	0.00163	CcSEcCtD
Rosiglitazone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000157	0.00162	CcSEcCtD
Rosiglitazone—Rash—Fluorouracil—urinary bladder cancer	0.000156	0.00161	CcSEcCtD
Rosiglitazone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000156	0.00161	CcSEcCtD
Rosiglitazone—Headache—Fluorouracil—urinary bladder cancer	0.000155	0.0016	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000154	0.0016	CcSEcCtD
Rosiglitazone—Asthenia—Etoposide—urinary bladder cancer	0.000154	0.0016	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000154	0.0016	CcSEcCtD
Rosiglitazone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000153	0.00159	CcSEcCtD
Rosiglitazone—Back pain—Methotrexate—urinary bladder cancer	0.000153	0.00158	CcSEcCtD
Rosiglitazone—Pruritus—Etoposide—urinary bladder cancer	0.000152	0.00157	CcSEcCtD
Rosiglitazone—Nausea—Gemcitabine—urinary bladder cancer	0.000149	0.00155	CcSEcCtD
Rosiglitazone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000148	0.00154	CcSEcCtD
Rosiglitazone—Rash—Cisplatin—urinary bladder cancer	0.000148	0.00153	CcSEcCtD
Rosiglitazone—Dermatitis—Cisplatin—urinary bladder cancer	0.000148	0.00153	CcSEcCtD
Rosiglitazone—Malnutrition—Epirubicin—urinary bladder cancer	0.000148	0.00153	CcSEcCtD
Rosiglitazone—Diarrhoea—Etoposide—urinary bladder cancer	0.000147	0.00152	CcSEcCtD
Rosiglitazone—Nausea—Fluorouracil—urinary bladder cancer	0.000147	0.00152	CcSEcCtD
Rosiglitazone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000147	0.00152	CcSEcCtD
Rosiglitazone—Anaemia—Methotrexate—urinary bladder cancer	0.000146	0.00151	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000146	0.00151	CcSEcCtD
Rosiglitazone—Back pain—Epirubicin—urinary bladder cancer	0.000143	0.00148	CcSEcCtD
Rosiglitazone—Dizziness—Etoposide—urinary bladder cancer	0.000142	0.00147	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000142	0.00147	CcSEcCtD
Rosiglitazone—Leukopenia—Methotrexate—urinary bladder cancer	0.000141	0.00146	CcSEcCtD
Rosiglitazone—Nausea—Cisplatin—urinary bladder cancer	0.000139	0.00144	CcSEcCtD
Rosiglitazone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000137	0.00141	CcSEcCtD
Rosiglitazone—Anaemia—Epirubicin—urinary bladder cancer	0.000136	0.00141	CcSEcCtD
Rosiglitazone—Rash—Etoposide—urinary bladder cancer	0.000135	0.0014	CcSEcCtD
Rosiglitazone—Dermatitis—Etoposide—urinary bladder cancer	0.000135	0.0014	CcSEcCtD
Rosiglitazone—Headache—Etoposide—urinary bladder cancer	0.000135	0.00139	CcSEcCtD
Rosiglitazone—Arthralgia—Methotrexate—urinary bladder cancer	0.000134	0.00139	CcSEcCtD
Rosiglitazone—Myalgia—Methotrexate—urinary bladder cancer	0.000134	0.00139	CcSEcCtD
Rosiglitazone—Leukopenia—Epirubicin—urinary bladder cancer	0.000132	0.00137	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—urinary bladder cancer	0.000132	0.00137	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000129	0.00133	CcSEcCtD
Rosiglitazone—Infection—Methotrexate—urinary bladder cancer	0.000128	0.00132	CcSEcCtD
Rosiglitazone—Nausea—Etoposide—urinary bladder cancer	0.000128	0.00132	CcSEcCtD
Rosiglitazone—Hypertension—Epirubicin—urinary bladder cancer	0.000127	0.00132	CcSEcCtD
Rosiglitazone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000126	0.00131	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—urinary bladder cancer	0.000126	0.00131	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000126	0.0013	CcSEcCtD
Rosiglitazone—Arthralgia—Epirubicin—urinary bladder cancer	0.000126	0.0013	CcSEcCtD
Rosiglitazone—Myalgia—Epirubicin—urinary bladder cancer	0.000126	0.0013	CcSEcCtD
Rosiglitazone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000122	0.00127	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00012	0.00125	CcSEcCtD
Rosiglitazone—Oedema—Epirubicin—urinary bladder cancer	0.00012	0.00125	CcSEcCtD
Rosiglitazone—Infection—Epirubicin—urinary bladder cancer	0.00012	0.00124	CcSEcCtD
Rosiglitazone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000118	0.00122	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000118	0.00122	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—urinary bladder cancer	0.000118	0.00122	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000117	0.00121	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000116	0.0012	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—urinary bladder cancer	0.000116	0.0012	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000111	0.00115	CcSEcCtD
Rosiglitazone—Oedema—Doxorubicin—urinary bladder cancer	0.000111	0.00115	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000111	0.00115	CcSEcCtD
Rosiglitazone—Fatigue—Methotrexate—urinary bladder cancer	0.000111	0.00115	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—urinary bladder cancer	0.000111	0.00115	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00011	0.00114	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000109	0.00113	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000109	0.00113	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000104	0.00108	CcSEcCtD
Rosiglitazone—Fatigue—Epirubicin—urinary bladder cancer	0.000104	0.00108	CcSEcCtD
Rosiglitazone—Constipation—Epirubicin—urinary bladder cancer	0.000103	0.00107	CcSEcCtD
Rosiglitazone—Urticaria—Methotrexate—urinary bladder cancer	0.000102	0.00106	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000102	0.00105	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	9.62e-05	0.000996	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—urinary bladder cancer	9.61e-05	0.000995	CcSEcCtD
Rosiglitazone—Urticaria—Epirubicin—urinary bladder cancer	9.57e-05	0.000991	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—urinary bladder cancer	9.53e-05	0.000987	CcSEcCtD
Rosiglitazone—Asthenia—Methotrexate—urinary bladder cancer	9.23e-05	0.000956	CcSEcCtD
Rosiglitazone—Pruritus—Methotrexate—urinary bladder cancer	9.1e-05	0.000943	CcSEcCtD
Rosiglitazone—Urticaria—Doxorubicin—urinary bladder cancer	8.85e-05	0.000917	CcSEcCtD
Rosiglitazone—Diarrhoea—Methotrexate—urinary bladder cancer	8.8e-05	0.000912	CcSEcCtD
Rosiglitazone—Asthenia—Epirubicin—urinary bladder cancer	8.64e-05	0.000895	CcSEcCtD
Rosiglitazone—Pruritus—Epirubicin—urinary bladder cancer	8.52e-05	0.000882	CcSEcCtD
Rosiglitazone—Dizziness—Methotrexate—urinary bladder cancer	8.51e-05	0.000881	CcSEcCtD
Rosiglitazone—Diarrhoea—Epirubicin—urinary bladder cancer	8.24e-05	0.000853	CcSEcCtD
Rosiglitazone—Rash—Methotrexate—urinary bladder cancer	8.11e-05	0.00084	CcSEcCtD
Rosiglitazone—Dermatitis—Methotrexate—urinary bladder cancer	8.11e-05	0.000839	CcSEcCtD
Rosiglitazone—Headache—Methotrexate—urinary bladder cancer	8.06e-05	0.000835	CcSEcCtD
Rosiglitazone—Asthenia—Doxorubicin—urinary bladder cancer	7.99e-05	0.000828	CcSEcCtD
Rosiglitazone—Dizziness—Epirubicin—urinary bladder cancer	7.96e-05	0.000825	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—urinary bladder cancer	7.88e-05	0.000816	CcSEcCtD
Rosiglitazone—Nausea—Methotrexate—urinary bladder cancer	7.64e-05	0.000791	CcSEcCtD
Rosiglitazone—Diarrhoea—Doxorubicin—urinary bladder cancer	7.62e-05	0.000789	CcSEcCtD
Rosiglitazone—Rash—Epirubicin—urinary bladder cancer	7.59e-05	0.000786	CcSEcCtD
Rosiglitazone—Dermatitis—Epirubicin—urinary bladder cancer	7.59e-05	0.000785	CcSEcCtD
Rosiglitazone—Headache—Epirubicin—urinary bladder cancer	7.54e-05	0.000781	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—urinary bladder cancer	7.37e-05	0.000763	CcSEcCtD
Rosiglitazone—Nausea—Epirubicin—urinary bladder cancer	7.15e-05	0.000741	CcSEcCtD
Rosiglitazone—Rash—Doxorubicin—urinary bladder cancer	7.02e-05	0.000727	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—urinary bladder cancer	7.02e-05	0.000727	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—urinary bladder cancer	6.98e-05	0.000723	CcSEcCtD
Rosiglitazone—Nausea—Doxorubicin—urinary bladder cancer	6.62e-05	0.000685	CcSEcCtD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.26e-05	0.000269	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—SRC—urinary bladder cancer	2.24e-05	0.000266	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.24e-05	0.000266	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—ENO2—urinary bladder cancer	2.22e-05	0.000263	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—HPGDS—urinary bladder cancer	2.22e-05	0.000263	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	2.21e-05	0.000263	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.21e-05	0.000263	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.2e-05	0.000262	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.2e-05	0.000261	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.19e-05	0.00026	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.16e-05	0.000256	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.15e-05	0.000255	CbGpPWpGaD
Rosiglitazone—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	2.13e-05	0.000253	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—GSTP1—urinary bladder cancer	2.13e-05	0.000253	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.12e-05	0.000251	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	2.1e-05	0.000249	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—ENO2—urinary bladder cancer	2.1e-05	0.000249	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	2.09e-05	0.000248	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.08e-05	0.000247	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.07e-05	0.000246	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.06e-05	0.000244	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.03e-05	0.000242	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	2.03e-05	0.000242	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.02e-05	0.000239	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.01e-05	0.000239	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.99e-05	0.000236	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—TYMP—urinary bladder cancer	1.98e-05	0.000235	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—TYMS—urinary bladder cancer	1.98e-05	0.000235	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.97e-05	0.000235	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—ESR1—urinary bladder cancer	1.97e-05	0.000235	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—TYMP—urinary bladder cancer	1.97e-05	0.000234	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—EGFR—urinary bladder cancer	1.96e-05	0.000233	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—GSTM1—urinary bladder cancer	1.95e-05	0.000232	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—NCOR1—urinary bladder cancer	1.95e-05	0.000232	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.95e-05	0.000231	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.92e-05	0.000228	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.9e-05	0.000226	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.89e-05	0.000225	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.87e-05	0.000222	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—GPX1—urinary bladder cancer	1.87e-05	0.000222	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—TNF—urinary bladder cancer	1.87e-05	0.000222	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—KRAS—urinary bladder cancer	1.85e-05	0.00022	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—ERCC2—urinary bladder cancer	1.84e-05	0.000218	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PLAU—urinary bladder cancer	1.81e-05	0.000215	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NAT2—urinary bladder cancer	1.79e-05	0.000213	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.79e-05	0.000212	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NAT2—urinary bladder cancer	1.78e-05	0.000212	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.77e-05	0.000211	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	1.77e-05	0.00021	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—TYMP—urinary bladder cancer	1.77e-05	0.00021	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.73e-05	0.000206	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.73e-05	0.000206	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.73e-05	0.000205	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.72e-05	0.000205	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.7e-05	0.000202	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.7e-05	0.000202	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NQO1—urinary bladder cancer	1.69e-05	0.000201	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.67e-05	0.000199	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.63e-05	0.000193	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.62e-05	0.000193	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.62e-05	0.000192	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.61e-05	0.000191	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NAT2—urinary bladder cancer	1.6e-05	0.00019	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.58e-05	0.000187	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.56e-05	0.000185	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.55e-05	0.000184	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.55e-05	0.000184	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.54e-05	0.000183	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.54e-05	0.000183	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—RRM2—urinary bladder cancer	1.54e-05	0.000183	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.51e-05	0.00018	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.49e-05	0.000177	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.49e-05	0.000177	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IGF1—urinary bladder cancer	1.47e-05	0.000175	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.47e-05	0.000175	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.47e-05	0.000175	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.46e-05	0.000173	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.45e-05	0.000172	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.44e-05	0.000171	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.43e-05	0.00017	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.43e-05	0.00017	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—HPGDS—urinary bladder cancer	1.42e-05	0.000169	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ENO2—urinary bladder cancer	1.42e-05	0.000169	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.42e-05	0.000169	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.41e-05	0.000168	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	1.41e-05	0.000167	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.39e-05	0.000165	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.38e-05	0.000165	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.38e-05	0.000164	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTT1—urinary bladder cancer	1.38e-05	0.000164	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—RRM2—urinary bladder cancer	1.38e-05	0.000164	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.38e-05	0.000164	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.37e-05	0.000163	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.37e-05	0.000163	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.37e-05	0.000162	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.36e-05	0.000162	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.36e-05	0.000162	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—RHOA—urinary bladder cancer	1.35e-05	0.00016	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.35e-05	0.00016	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.32e-05	0.000157	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.31e-05	0.000156	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—TYMS—urinary bladder cancer	1.31e-05	0.000156	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	1.29e-05	0.000154	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	1.29e-05	0.000154	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.29e-05	0.000154	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.29e-05	0.000153	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.28e-05	0.000152	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.28e-05	0.000152	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.27e-05	0.000151	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.27e-05	0.000151	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.26e-05	0.000149	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.25e-05	0.000148	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.24e-05	0.000147	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.24e-05	0.000147	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.22e-05	0.000145	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.22e-05	0.000145	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.21e-05	0.000144	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.18e-05	0.00014	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.18e-05	0.00014	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.16e-05	0.000138	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.16e-05	0.000138	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.16e-05	0.000138	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000137	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000136	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	1.14e-05	0.000136	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.14e-05	0.000135	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IL2—urinary bladder cancer	1.13e-05	0.000135	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	0.000134	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.12e-05	0.000133	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.11e-05	0.000132	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.11e-05	0.000132	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.1e-05	0.000131	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTGS2—urinary bladder cancer	1.1e-05	0.000131	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.07e-05	0.000128	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.06e-05	0.000126	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.03e-05	0.000122	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—MYC—urinary bladder cancer	1.03e-05	0.000122	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—EP300—urinary bladder cancer	1.02e-05	0.000121	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.99e-06	0.000119	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ENO2—urinary bladder cancer	9.95e-06	0.000118	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	9.95e-06	0.000118	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.9e-06	0.000118	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—SRC—urinary bladder cancer	9.89e-06	0.000117	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PPARG—urinary bladder cancer	9.81e-06	0.000117	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.76e-06	0.000116	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.71e-06	0.000115	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	9.66e-06	0.000115	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	9.62e-06	0.000114	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTEN—urinary bladder cancer	9.61e-06	0.000114	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTP1—urinary bladder cancer	9.57e-06	0.000114	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.51e-06	0.000113	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	9.47e-06	0.000113	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CREBBP—urinary bladder cancer	9.42e-06	0.000112	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NQO1—urinary bladder cancer	9.39e-06	0.000112	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.31e-06	0.000111	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PPARG—urinary bladder cancer	9.28e-06	0.00011	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.26e-06	0.00011	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—EP300—urinary bladder cancer	9.16e-06	0.000109	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.11e-06	0.000108	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	8.95e-06	0.000106	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	8.91e-06	0.000106	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—TYMS—urinary bladder cancer	8.89e-06	0.000106	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	8.84e-06	0.000105	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	8.84e-06	0.000105	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTM1—urinary bladder cancer	8.79e-06	0.000104	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NCOR1—urinary bladder cancer	8.79e-06	0.000104	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.71e-06	0.000104	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	8.68e-06	0.000103	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	8.59e-06	0.000102	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	8.47e-06	0.000101	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GPX1—urinary bladder cancer	8.42e-06	0.0001	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	8.31e-06	9.88e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.31e-06	9.87e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ERCC2—urinary bladder cancer	8.27e-06	9.82e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—KRAS—urinary bladder cancer	8.19e-06	9.73e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NQO1—urinary bladder cancer	8.02e-06	9.53e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	7.98e-06	9.49e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.95e-06	9.44e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	7.9e-06	9.39e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	7.89e-06	9.38e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	7.89e-06	9.38e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	7.83e-06	9.31e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	7.81e-06	9.29e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.79e-06	9.25e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—MTHFR—urinary bladder cancer	7.77e-06	9.23e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTGS2—urinary bladder cancer	7.72e-06	9.17e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.58e-06	9e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	7.57e-06	8.99e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	7.56e-06	8.98e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	7.42e-06	8.82e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	7.34e-06	8.73e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	7.3e-06	8.67e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—TYMS—urinary bladder cancer	7.28e-06	8.65e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—urinary bladder cancer	7.28e-06	8.65e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	7.26e-06	8.63e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	7.26e-06	8.63e-05	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—EP300—urinary bladder cancer	7.22e-06	8.57e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	7.2e-06	8.55e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	7.2e-06	8.55e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	6.98e-06	8.29e-05	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—HRAS—urinary bladder cancer	6.96e-06	8.27e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	6.95e-06	8.26e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GPX1—urinary bladder cancer	6.89e-06	8.19e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	6.83e-06	8.11e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.79e-06	8.07e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	6.77e-06	8.04e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTEN—urinary bladder cancer	6.73e-06	8e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	6.69e-06	7.95e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.47e-06	7.69e-05	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—EP300—urinary bladder cancer	6.42e-06	7.63e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	6.42e-06	7.62e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTEN—urinary bladder cancer	6.36e-06	7.56e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	6.36e-06	7.56e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	6.34e-06	7.53e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PPARG—urinary bladder cancer	6.3e-06	7.49e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	6.22e-06	7.39e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	6.15e-06	7.31e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	6.15e-06	7.31e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	6.09e-06	7.23e-05	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—EP300—urinary bladder cancer	6.07e-06	7.21e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CREBBP—urinary bladder cancer	6.05e-06	7.19e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	5.89e-06	7e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	5.78e-06	6.87e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	5.66e-06	6.72e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	5.44e-06	6.46e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	5.43e-06	6.46e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	5.2e-06	6.18e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PPARG—urinary bladder cancer	5.16e-06	6.13e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5e-06	5.94e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	4.99e-06	5.92e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTGS2—urinary bladder cancer	4.96e-06	5.89e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.95e-06	5.89e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	4.45e-06	5.29e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.41e-06	5.24e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.35e-06	5.17e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTEN—urinary bladder cancer	4.32e-06	5.14e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.23e-06	5.03e-05	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.15e-06	4.93e-05	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—EP300—urinary bladder cancer	4.12e-06	4.9e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.09e-06	4.86e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.06e-06	4.82e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	3.88e-06	4.61e-05	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—EP300—urinary bladder cancer	3.7e-06	4.4e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.57e-06	4.24e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.54e-06	4.2e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.47e-06	4.12e-05	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.4e-06	4.04e-05	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.37e-06	4.01e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.02e-06	3.59e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—EP300—urinary bladder cancer	2.88e-06	3.43e-05	CbGpPWpGaD
